Last updated: June 13, 2023
Sponsor: Silverstein Eye Centers
Overall Status: Completed
Phase
4
Condition
Eye Disease
Vision Loss
Eye Disorders/infections
Treatment
Dexycu, 9% Intraocular Suspension
Dextenza (dexamethasone ophthalmic insert) 0.4mg
Omidria
Clinical Study ID
NCT04316936
1
All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients 18 years of age or older, undergoing routine, uncomplicated cataract surgery.
Exclusion
Exclusion Criteria:
- Any history of corneal dystrophy, corneal surgery within 6 months of cataract surgery,previous intraocular surgery, any concomitant eye drop use besides artificial tears,previous ocular trauma, or a history of treated glaucoma. No additional procedures canbe done at the time of cataract surgery (e.g., stent placement, endo-laser, etc.), butfemto-second laser-assisted surgery is permitted.
Study Design
Total Participants: 15
Treatment Group(s): 4
Primary Treatment: Dexycu, 9% Intraocular Suspension
Phase: 4
Study Start date:
December 10, 2019
Estimated Completion Date:
December 23, 2020
Study Description
Connect with a study center
Silverstein Eye Centers
Kansas City, Missouri 64133
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.